Cytocom subsidiary inc
WebDec 31, 2024 · Old Cytocom was renamed "Cytocom Subsidiary Inc." and the Company was renamed "Cytocom, Inc. " Upon completion of the Merger, each outstanding share of Old Cytocom common stock, each outstanding share of Old Cytocom preferred stock that was not, by its terms, converted into shares of Old Cytocom common stock immediately … WebOct 21, 2024 · Cytocom, Inc. is a leader in immune modulation for the treatment of serious disease is a company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.
Cytocom subsidiary inc
Did you know?
WebJul 6, 2024 · On July 27, 2024, Cytocom, Inc., formerly known as Cleveland BioLabs, Inc. (the “Company” or “Cleveland BioLabs”), High Street Acquisition Corp., a Delaware … WebOn June 24, 2024, Cytocom completed the acquisition of ImQuest Life Sciences, Inc. and its subsidiaries (“ImQuest”) in accordance with the Agreement and Plan of Merger by …
Web63 Uas jobs available in Ashburn Farm, VA on Indeed.com. Apply to Program Manager, Intelligence Analyst, Information Systems Manager and more! WebEngineering Supplies, inc is headquartered Virginia, USA. Since we were founded in 1989, we've focused on providing innovative solutions for education and business. Get in …
WebAug 5, 2024 · Cytocom Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary... WebContact Email [email protected]. Phone Number 1-888-629-4155. Cytocom, Inc. a specialty biotech company, founded by patients, specializing in repurposing of drugs that deploys their patented therapies focused on the activation and rebalancing of the body’s immune system. Stimulating the body’s immune system remains one of the most …
WebAug 5, 2024 · FORT COLLINS, Colo., Aug. 5, 2024 — Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. The all-stock transaction, first …
WebAug 31, 2024 · Cytocom, Inc. emerged as a publicly-traded entity following the merger between the former Cleveland BioLabs and the formerly private Cytocom Inc., completed on July 27, 2024. “The new corporate name, Statera BioPharma and updated ticker symbol mark the latest event in a transformative year for the company,” said Michael K. Handley, … faresin fs 7.32WebOct 21, 2024 · Cytocom, Inc. is a leader in immune modulation for the treatment of serious disease is a company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and... fare slownikWebIn December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. The Company also transferred certain rights to Cytocom, including rights, titles, and interests in or relating to intellectual property, which are further described in the section of ... fares mashal mdWebJul 20, 2024 · Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform that is designed to … correct inventorship patent applicationWebOct 21, 2024 · Cytocom, Inc. is a leader in immune modulation for the treatment of serious disease is a company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. correction action 日本語WebIn August 2024, Old Cytocom, now a wholly owned subsidiary of the Company, entered into an employment agreement with Mr. Handley, who currently serves as the Chief Executive Officer of Old... correctional cable tv addressWebApr 12, 2024 · Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share. Benzinga 95d. correctio beispiel